

PROJECT ACQUISITION AGREEMENT made as of December 23, 2025

BETWEEN: **AZIMUT EXPLORATION INC.**, a corporation duly incorporated under the *Business Corporations Act* (Québec), having its head office at 110 De La Barre Street, Suite 224, Longueuil, QC J4K 1A3, represented for the purposes hereof by Jean-Marc Lulin, President and Chief Executive Officer, duly authorized as he so declares;

(hereinafter, the “**Vendor**”)

AND: **Li-FT Power Ltd.**, a corporation duly incorporated under the *Business Corporations Act* (British Columbia), having its head office at 1218-1030 West Georgia Street Vancouver, BC V6E 2Y3, represented for the purposes hereof by Francis MacDonald, President and Chief Executive Officer, duly authorized as he so declares;

(hereinafter, the “**Purchaser**”)

(collectively, the “**Parties**” and each of them, a “**Party**”)

RECITALS:

- A. The Vendor owns a 50% undivided interest in 649 exclusive exploration rights commonly known as the Galinée Lithium project, which are located in the Province of Québec and are more particularly described and located as set forth in Schedule “A” hereto (the “**Project**”); and
- B. The Parties have agreed to complete the following transaction relating to the Project on the terms and subject to the conditions set forth in this Agreement (collectively, the “**Transaction**”).

THEREFORE, the Parties agree as follows:

ARTICLE 1 - INTERPRETATION

1.1 Definitions

Whenever used in this Agreement, the following words and terms shall have the meanings set out below:

“**Affiliate**” of any Person means, at the time such determination is being made, any other Person controlling, controlled by or under common control with such first Person;

“**Agreement**” means this Project Acquisition Agreement, including without limitation Schedule “A” “Description of Project and Exclusive Exploration Rights” and all written instruments supplementing or amending or confirming this Agreement and references to “Article” or “Section” mean and refer to the specified Article or Section of this Agreement;

“**Business Day**” means a day, other than a Saturday or Sunday, on which the principal commercial banks located in the province of Québec are open for business during normal banking hours;

“Closing Date” means the fifth Business Day following the date on which the conditions set out in Article 8 are satisfied or waived, or such other date as mutually agreed to by the Parties;

“Closing Date Consideration Shares” means 2,000,000 Purchaser Shares;

“Consideration Shares” means the Closing Date Consideration Shares and the Deferred Consideration Shares, if any.

“Deferred Consideration” means an amount of \$1,500,000;

“Encumbrance” means, whether registered or registrable or recorded or recordable, and regardless of how created or arising, any hypothec, mortgage, deed of trust, pledge, lien, security interest, adverse interest, net profits interest, royalty, overriding royalty interest, other payment out of production, claim, option to acquire or sell, off-take agreement, third party right of first refusal or pre-emptive right, other third person interest or other encumbrance or burden of any nature, whether contingent or absolute, and any agreement to grant, or right capable of becoming, any of the foregoing;

“Governmental Authority” means any governmental regulatory or administrative body agency or authority, any court or judicial authority or any public regulatory authority, whether international, federal, provincial or local;

“JV Agreement” means the option and joint venture agreement (*contrat d’option et de coentreprise*) in respect of the Project dated as of June 20, 2018, by and between SOQUEM Inc. (“**SOQUEM**”) and the Vendor, as the same may be amended, restated or supplemented from time to time;

“Laws” means any and all laws (statutory, common or otherwise), statutes, regulations, statutory rules, regulatory instruments, principles of law, orders, injunctions, judgments, published policies and guidelines (to the extent that they have the force of law), and terms and conditions of any grant of approval, permission, authority or license of any Governmental Authority, statutory body or self-regulatory authority, and the term “applicable” with respect to such Laws and in the context that refers to one or more Persons means that such Laws apply to such Person or Persons or its or their business, undertaking, property or securities and emanate from a Person having jurisdiction over the Person or Persons or its or their business, undertaking, property or securities;

“Material Adverse Effect” means a state of facts, event, change, effect or circumstance that, when considered either individually or in the aggregate together with all other adverse changes, effects or circumstances with respect to which such phrase is used in this Agreement, is materially adverse to, or would reasonably be expected to have a material adverse effect on: (a) the financial condition or results of operations or prospects of the Project, other than those resulting from industry-wide conditions or general economic conditions affecting the mining industry (except to the extent disproportionately affecting the Project); or (b) the ability of a Party to consummate the Transaction;

“MRNF” means the Quebec Ministry of Natural Resources and Forests;

“Parties” and **“Party”** shall have the meanings ascribed thereto in the preamble;

“Permitted Encumbrances” means (i) all reservations, limitations, provisos and conditions expressed in the original grant of title of the lands and premises comprising the Property from a Governmental Authority; (ii) all rights of expropriation of any Governmental Authority; (iii) any easement or right-of-way to any utility (either municipal, private or public) whether it be for gas,

water, electricity and/or telephone; (iv) public reservations, public utilities, encumbrances or other restrictions in the use of the Property which, overall, do not materially reduce the value of all or part thereof or of the use which can be made thereof; and (v) such Encumbrances as may be approved by the Parties or created pursuant to the provisions of this Agreement;

“**Person**” includes any individual, firm, partnership, joint venture, venture capital fund, association, trust, trustee, executor, administrator, legal personal representative, estate, group, body corporate, corporation, company, unincorporated association or organization, Governmental Authority, syndicate or other entity, whether or not having legal status;

“**Project**” shall have the meaning ascribed thereto in the Recitals;

“**Purchaser Shares**” means common shares in the capital of the Purchaser;

“**Representative**” means, with respect to any Person, any director, officer or employee of such Person and any agent, consultant, legal, accounting, financial or other advisor or other representative authorized by such Person to represent or act on behalf of such Person;

“**Time of Closing**” shall have the meaning ascribed thereto in Section 2.2;

“**Transaction**” shall have the meaning ascribed thereto in the Recitals; and

“**TSX-V**” means the TSX Venture Exchange.

1.2 **Certain Rules of Interpretation**

In this Agreement:

(a) **Time** – Time is of the essence in the performance of the Parties’ respective obligations.

(b) **Business Day** – Whenever payment is to be made or action to be taken under this Agreement is required to be made or taken on a day other than a Business Day, such payment shall be made or action taken on the next Business Day following such day.

1.3 **Severability**

If any provision of this Agreement is determined to be void or unenforceable, in whole or in part, it shall be deemed not to affect or impair the validity of any other provision of this Agreement.

1.4 **Entire Agreement**

Upon the Parties’ execution of this Agreement, this Agreement shall constitute the entire agreement between the Parties pertaining to the subject matter of this Agreement and shall supersede all prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties. There are no warranties, representations or other agreements between the Parties in connection with the subject matter of this Agreement except as specifically set forth in this Agreement.

1.5 **Applicable Law**

This Agreement shall be governed in all respects by the laws in force in the Province of Québec.

1.6 Knowledge

In this Agreement, the phrase “to the knowledge of” any Person, “to the best knowledge of” any Person, “known to” any Person, “of which it is aware” or any similar phrase means, unless otherwise indicated, (a) with respect to any Person who is an individual, the actual knowledge of such Person, and (b) with respect to any Person who is not an individual, the actual knowledge of the senior officers and directors of such Person and its affiliates after reasonable enquiry, and to the extent that such reasonable enquiry was not conducted, includes the knowledge that a reasonable Person would have had if such reasonable enquiry had been conducted.

1.7 AZtechMine™

For certainty, nothing in this Agreement shall be interpreted so as to require the Vendor to disclose any information regarding AZtechMine™ (the proprietary targeting methodology used by the Vendor to identify targets from the processing of regional scale geoscientific data).

ARTICLE 2 - PROJECT INTEREST AND CONSIDERATION SHARES

2.1 Purchase and Sale

Subject to Article 8, the Vendor hereby assigns, transfers and sells to the Purchaser all of its rights, titles and interests in and to the Project free of all Encumbrances (other than Permitted Encumbrances) (the “**Acquired Interest**”) effective at the Time of Closing. The consideration payable by Purchaser for the Acquired Interest, exclusive of all applicable sales and transfer taxes, shall be the aggregate of: (i) the Closing Date Consideration Shares; (ii) the Deferred Consideration in accordance with Article 4; and (iii) a 1.4% Net Smelter Return Royalty in accordance with Article 3.

2.2 Closing Date

(a) Closing of the Transaction will be completed virtually through exchange of electronic documents and be effective at 10:00 a.m. (Eastern Time) (the “**Time of Closing**”) on the Closing Date.

(b) At the Time of Closing, the Purchaser shall issue the Closing Date Consideration Shares to the Vendor.

(c) At the Time of Closing, the Vendor shall execute and provide the Purchaser with a mining right transfer form evidencing the transfer of 100% of the Vendor’s interest in the Project from the Vendor in favour of the Purchaser, in the form provided for by the MRNF as of the Closing Date, together with any other deed, document or instrument necessary or useful for such transfer, the whole to Purchaser’s satisfaction (the “**Title Documents**”). The Purchaser shall be responsible to pay any statutory or administrative fee or duty in relation to such transfer of mining rights and to the registration thereof.

2.3 Acknowledgements of the Parties

(a) The Parties hereby acknowledge and agree that the Consideration Shares are subject to a statutory hold period of not more than four (4) months and one (1) day from the date of issue and the certificate representing the Consideration Shares will be endorsed with a legend setting out resale restrictions under applicable securities legislation. The Vendor acknowledges it is solely responsible for compliance with such resale restriction period, the whole in accordance with applicable securities legislation and TSX-V rules and policies.

(b) The Parties hereby acknowledge and agree that the Consideration Shares are being issued to the Vendor on a prospectus exempt basis and in reliance on the prospectus exemption provided under Section 2.13 (Petroleum, natural gas and mining properties) of *Regulation 45-106 Respecting Prospectus Exemptions*.

2.4 Covenants

(a) Subject to the Closing Date occurring, the Vendor covenants and agrees to (i) deliver to the Purchaser all digital data relating to the Project in its control or possession in a timely manner as promptly as possible after the date hereof, but in no event later than on the Closing Date, (ii) deliver to the Purchaser, within 30 days of the Closing Date, all tangible data relating to the Project in its control or possession, including without limitation all maps, assays, surveys, drill logs, samples (including all drill cores), metallurgical, geological, geophysical, geochemical and engineering data in respect thereof; and (iii) make and do all such further acts and things, to execute and deliver such instruments, agreements and documents prepared by or on behalf of the Purchaser as it shall consider reasonably necessary to give effect to the Transaction. The Parties shall cooperate in the preparation, submission, execution and delivery of all such instruments, agreements, documents, notices and filings. The Parties shall request expedited treatment of any such filings and shall promptly make, prepare, execute and deliver any appropriate or necessary subsequent or supplemental instruments, agreements, documents, notices and filings in order to give effect to the transactions contemplated by this Agreement.

(b) If requested by the Purchaser, the Vendor shall collaborate without delay in the filing of an application for registration in the land register of the deed evidencing the Transaction in accordance with the *Act respecting duties on transfer of immovables* (Québec). If the deed evidencing the Transaction is not registered in the land register on or before the ninetieth day after the date of the transfer, the Purchaser shall at its own cost prepare and file on or before that ninetieth day following the Closing Date a notice of disclosure of the Transaction containing the information listed in section 10.1 of the *Act respecting duties on transfer of immovables* (Québec) with the municipality or municipalities in whose territory the Project is situated.

(c) The Vendor agrees to assist the Purchaser in providing the information listed in section 10.1 of the *Act respecting duties on transfer of immovables* (Québec) summarized hereinafter:

(i) Name and address of head office or principal place of business of the Purchaser and of the Vendor;

(ii) the Québec business number assigned to it under the *Act respecting the legal publicity of enterprises* (chapter P-44.1) or the identification number assigned to it by the Minister of Revenue, if applicable, of the Purchaser and of the Vendor;

(iii) the name, position and contact information of each person authorized to act on behalf of the Purchaser and of the Vendor;

(iv) the name of the members of a professional order who have rendered services to the Purchaser and the Vendor in the course of the transfer of the immovable;

(v) the identity of the owner of the Project that appears in the deed registered in the land register;

(vi) the other particulars that must appear in the application for registration in the land register of a deed evidencing the transfer of an immovable under the first paragraph of section 9 of the *Act respecting duties on transfer of immovables* (Québec); and

(vii) copy of the private writing evidencing the transfer of the Project.

(d) The Vendor hereby agrees that it will promptly and timely submit to and file with MRNF, to the satisfaction of the Purchaser, all work conducted prior to the Closing Date with respect to the Project. From and after the Closing Date, until such time as the transfer and registration of the Project has been fully registered by MRNF in the name of the Purchaser, the Vendor shall take all such actions and do all such things, executed and deliver all such instruments, agreements, documents and notices in order to give effect to the Transaction and to ensure that the Purchaser has all rights at law of a holder of exclusive exploration rights.

ARTICLE 3 - NSR

3.1 Granting of NSR

The Parties acknowledge and agree that effective at the Time of Closing, the Vendor shall be granted a 1.4% Net Smelter Returns Royalty (the “**NSR**”) on the Project that is more particularly described in Schedule “B”.

ARTICLE 4 – DEFERRED PAYMENT

4.1 Deferred Payment

On the date which is on the earlier of: (a) 18 months following the Closing Date; and (b) three (3) Business Days following the public disclosure of a technical report with respect to the Project that includes an economic analysis of one or more development scenarios, the Purchaser shall pay in cash the Deferred Consideration (the “**Deferred Consideration Payment**”) to the Vendor, provided that if the Purchaser Shares are listed on the TSX-V or another Canadian recognized stock exchange at such time the Purchaser may elect, subject to the prior approval of the TSX-V

or such other stock exchange, to satisfy the Deferred Consideration Payment by the issuance of a number of Purchaser Shares equal to the Deferred Consideration divided by the volume weighted average price of the Purchaser Shares on the TSX-V or such other stock exchange for the 20 trading days preceding the date of issuance of such Purchaser Shares, the whole subject to the issuance of a maximum of 3,000,000 Purchaser Shares (the “**Deferred Consideration Shares**”), but provided further that the Purchaser shall not be entitled to exercise such share payment election if, based on such 20-day volume weighted average price, the Deferred Consideration Shares would have an aggregate value of less than the Deferred Consideration (\$1,500,000), in which case the Deferred Consideration Payment shall be satisfied in cash only.

ARTICLE 5 - REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

The Purchaser hereby represents and warrants (which representations and warranties shall survive the Closing Date) as follows:

5.1 Incorporation

The Purchaser is a valid and subsisting corporation duly incorporated and in good standing under the laws of the Province of British Columbia and has all requisite corporate power and authority to carry on its business as presently conducted and as presently proposed to be conducted, and to own, lease and operate all of its assets.

5.2 Capitalization

The authorized capital of the Purchaser consists of an unlimited number of common shares without par value, of which 47,351,267 are, as of the date hereof, issued and outstanding.

5.3 No Conflict

The entering into of this Agreement by the Purchaser and the consummation of the Transaction contemplated hereby, including without limitation the issuance of the Closing Date Consideration Shares to the Vendor, does not and will not conflict with and does not and will not result in a breach of any of the terms, conditions or provisions of the constating documents or by-laws of the Purchaser or any statute, law or regulation applicable to the Purchaser or any agreement or instrument to which the Purchaser is a party.

5.4 Due Authorization

(a) This Agreement and the Transaction contemplated hereby have been duly authorized by all necessary corporate action on the part of the Purchaser and constitute valid obligations of the Purchaser legally binding upon it and enforceable against it in accordance with its terms, subject however to the usual limitations with respect to enforcement imposed by law in connection with bankruptcy or similar proceedings and the availability of equitable remedies. The Purchaser has all corporate power and authority necessary to complete the Transaction.

(b) The Purchaser has the full power and authority to issue the Closing Date Consideration Shares. The issuance of the Closing Date Consideration Shares has been duly authorized by all necessary corporate action on the part of the Purchaser. At the Time of Closing, the Closing Date Consideration Shares will be validly issued, in accordance

with applicable law and rules of the TSX-V, as fully paid and non-assessable shares in the capital of the Purchaser and the Vendor will be the legal and registered owner of the Closing Date Consideration Shares and will have good title thereto free and clear of all Encumbrances.

5.5 Reporting Issuer Status

The Purchaser is a reporting issuer in each of the provinces and territories of Canada, is current and up-to-date in all material respects with all filings required to be made pursuant to applicable securities laws and is not included on the list of defaulting reporting issuers maintained by the respective securities commissions in such jurisdictions. All such filings are in compliance in all material respects with laws and do not contain any untrue statements of a material fact or omit to state a material fact.

5.6 Public Listing

The issued and outstanding common shares of the Purchaser are listed for trading on the TSX-V.

5.7 No Cease Trade Order

No order ceasing or suspending trading in the common shares of the Purchaser nor prohibiting the issuance of the Closing Date Consideration Shares or the sale of such securities has been issued by any securities commission of any Province or Territory of Canada to the Purchaser or its directors or officers which is currently in effect, and to the best of the Purchaser's knowledge, no such investigations or proceedings for such purposes are pending or threatened.

5.8 No Broker

No broker, finder, agent, financial advisor or investment advisor (each a "**Finder**") acted, directly or indirectly, for the Purchaser in connection with the Transaction. The Purchaser is not a party to any contract with any Finder and does not owe any compensation, including by way of the issuance of securities, to any Finder in respect of the Transaction.

5.9 Taxable Canadian corporation

The Purchaser is a "taxable Canadian corporation" within the meaning of the *Income Tax Act* (Canada).

ARTICLE 6 - REPRESENTATIONS AND WARRANTIES OF THE VENDOR

The Vendor hereby represents and warrants (which representations and warranties shall survive the Closing Date) as follows:

6.1 Incorporation

The Vendor is a valid and subsisting corporation duly incorporated and in good standing under the laws of the Province of Québec and has all requisite corporate power and authority to carry

on its business as presently conducted and as presently proposed to be conducted, and to own, lease and operate all of its assets.

6.2 Residence

The Vendor is not a non-resident of Canada within the meaning of the *Income Tax Act* (Canada) and the *Taxation Act* (Québec).

6.3 No Conflict

The entering into of this Agreement by the Vendor and the consummation of the Transaction contemplated hereby does not and will not conflict with and does not and will not result in a breach of any of the terms, conditions or provisions of the constating documents or by-laws of the Vendor or any statute, law or regulation applicable to the Vendor or any agreement or instrument to which the Vendor is a party.

6.4 Due Authorization

This Agreement and the Transaction contemplated hereby have been duly authorized by all necessary corporate action on the part of the Vendor and constitute valid obligations of the Vendor legally binding upon it and enforceable against it in accordance with its terms, subject however to the usual limitations with respect to enforcement imposed by law in connection with bankruptcy or similar proceedings and the availability of equitable remedies. The Vendor has all corporate power and authority necessary to complete the Transaction.

6.5 Project Representations

(a) The Vendor is the legal and registered owner of a 50% undivided interest in the Project, with good and marketable title thereto, and its 50% interest in the Project is duly recorded in the name of the Vendor, free and clear of all Encumbrances except for Permitted Encumbrances and the JV Agreement;

(b) The Vendor has provided the Purchaser copies of all maps, reports, assay results and other relevant technical data compiled by or in the possession of the Vendor with respect to the Project;

(c) Other than the Purchaser no Person has any agreement or option or any right or privilege capable of becoming an agreement or option for the purchase of the Project or any portion thereof or interest therein from the Vendor, other than pursuant to the transactions contemplated in this Agreement;

(d) The Project is in good standing under applicable Law and all work required to be performed and filed in respect thereof has been performed and filed, all taxes, royalties, rentals, fees, expenditures and other payments in respect thereof have been paid or incurred and all filings in respect thereof have been made;

(e) There is no material adverse claim against or challenge to the title to or ownership of the Project and the Vendor is not aware of any defects, failures or impairments in the

title of the Vendor to the Project whether or not an action, suit, proceeding or inquiry is pending or threatened and whether or not discovered by any third party;

(f) The exclusive exploration rights forming part of the Project are in good standing and no event, condition or occurrence exist that, after notice or lapse of time or both, would constitute a default under such exclusive exploration rights;

(g) Schedule "A" to this Agreement sets forth: (i) the record and anniversary dates for each exclusive exploration right forming part of the Project; and (ii) the aggregate amount of fees and work expenditures required to maintain such exclusive exploration rights in good standing, together with work expenditures incurred by the Vendor or any other registered owner during the period from January 1, 2025 to the date of this Agreement;

(h) The exclusive exploration rights forming part of the Project, as described in Schedule "A", are not located, in whole or in part in an agricultural zone within the meaning of an *Act respecting the preservation of agricultural land and agricultural activities*, CQLR c.P-41.1;

(i) All taxes, duties or other payments and charges due prior to the Closing Date with respect to the Project have been paid in full as of the Closing Date;

(j) There are no legal proceedings (whether or not purportedly on behalf of the Vendor) in progress, pending or, to the best of the Vendor's knowledge, threatened against or otherwise affecting the Vendor relating to the Project at Law or in equity and there is no judgment, decree, injunction, ruling, order or award of any tribunal outstanding against or affecting the Vendor relating to the Project;

(k) The Project exists entirely on Crown land and no surface rights associated with the Project are privately owned;

(l) The Vendor has full and unfettered access to the Project;

(m) The Vendor has not received any notice, whether written or oral, from any Governmental Authority of any revocation or intention to revoke any interest of the Vendor in the Project;

(n) To the best of the Vendor's knowledge, the Project does not lie within any protected area, reserve, reservation, reserved area or special needs lands as designated by any Governmental Authority having jurisdiction, that would impair the exploration for minerals or the development of a mining project on the Project;

(o) There are no orders or directions relating to environmental matters requiring any work, repairs, construction or capital expenditures with respect to the Project or the conduct of the business related to the Project, nor to the best of the Vendor's knowledge has any activity on the Project been in violation of any applicable environmental law, regulations or regulatory prohibition or order, and to the best of the Vendor's knowledge, conditions on and relating to the Project is in compliance with those laws, regulations, prohibitions and orders;

(p) To the best of the Vendor's knowledge, there has been no material spill, discharge, leak, emission, ejection, escape, dumping, or any release or threatened release of any kind, of any toxic or hazardous substance or waste (as defined by any applicable Law) from, on, in or under the Project or into the environment, except releases expressly permitted or otherwise authorized by applicable Law;

(q) To the best of the Vendor's knowledge, no toxic or hazardous substance or waste has been treated, disposed of or is located or stored on the Project as a result of activities of the Vendor or its predecessors in title or interest;

(r) To the best of the Vendor's knowledge, there is no pending or ongoing claims or actions taken by or on behalf of any First Nations, native or indigenous persons with respect to any lands included in the Project, but the Parties hereby acknowledge that no First Nation, native or indigenous persons were contacted by the Vendor in connection with the transactions hereby contemplated;

(s) No employees of the Vendor are associated with the Project;

(t) The assets included in the Project are capital properties to the Vendor for the purposes of the Income Tax Act (Canada) and are not inventory used in a business or in an adventure in the nature of a trade by the Vendor; and

(u) No act or proceeding has been taken by or against it in connection with its dissolution, liquidation, winding up, bankruptcy or reorganization or for the appointment of a trustee, receiver, manager or other administrator of the Vendor or its Project or assets nor, to its knowledge, is any such act or proceeding threatened. It has not sought protection under the *Bankruptcy and Insolvency Act* (Canada), the *Companies' Creditors Arrangement Act* (Canada) or similar legislation.

ARTICLE 7 - COVENANTS

7.1 Covenants of the Vendor

The Vendor covenants and agrees with the Purchaser that from the date hereof to the earlier of: (a) the Closing Date; and (b) the date of termination of this Agreement, as applicable, it will:

(a) maintain its interest in the Project in good standing under applicable Laws, perform all work required to be performed under applicable Law, pay all taxes, royalties, rentals, fees, expenditures and other payments required to be paid in respect thereof and make any necessary tax, governmental and other filings and payments and perform such other related and applicable obligations in respect of the Project in a timely fashion;

(b) take reasonable care to protect and safeguard the Project;

(c) not sell or dispose of or transfer possession of all or any portion of the Project, or any interest therein;

(d) not grant or permit to exist any Encumbrances on its rights to the Project, other than with the consent of the Purchaser;

(e) promptly advise the Purchaser orally and, if then requested, in writing, with the full particulars of any:

(i) event occurring subsequent to the date of this Agreement that would render any representation or warranty of the Vendor contained in this Agreement (except any such representation or warranty which speaks as of a date prior to the date of this Agreement), if made on or as of the date of such event or the Closing Date, untrue or inaccurate in any material respect; and

(ii) breach by the Vendor of any covenant or agreement contained in this Agreement;

(f) perform all obligations required or desirable to be performed by it under this Agreement and shall do all such other acts and things as may be necessary or desirable in order to consummate and make effective, as soon as reasonably practicable, the transactions contemplated in this Agreement and without limiting the generality of the foregoing, the Vendor shall:

(i) use reasonable best efforts to obtain, if required, on or before the Closing Date, the approval of the TSX-V to complete the Transaction;

(ii) defend all lawsuits or other legal, regulatory or other proceedings challenging or affecting this Agreement or the consummation of the transactions contemplated hereby; and

(iii) use reasonable best efforts to have lifted or rescinded any injunction or restraining order or other order relating to it which may adversely affect the ability of the Parties to consummate the transactions contemplated hereby; and

(g) use all reasonable best efforts to satisfy all conditions precedent set forth in Section 8.1 and Section 8.3 of this Agreement.

7.2 Covenants of the Purchaser

The Purchaser covenants and agrees with the Vendor that from the date hereof to the earlier of: (a) Closing Date; and (b) the date of termination of this Agreement, as applicable, it will:

(a) promptly advise the Vendor orally and, if then requested, in writing, with the full particulars of any:

(i) event occurring subsequent to the date of this Agreement that would render any representation or warranty of the Purchaser contained in this Agreement (except any such representation or warranty which speaks as of a date prior to the date of this Agreement), if made on or as of the date of such event or the Closing Date, untrue or inaccurate in any material respect; and

- (ii) breach by the Purchaser of any covenant or agreement contained in this Agreement;
- (b) perform all obligations required or desirable to be performed by it under this Agreement and shall do all such other acts and things as may be necessary or desirable in order to consummate and make effective, as soon as reasonably practicable, the transactions contemplated in this Agreement and without limiting the generality of the foregoing, the Purchaser shall:
 - (i) use reasonable best efforts to obtain, on or before the Closing Date, the approval of the TSX-V to complete the Transaction;
 - (ii) defend all lawsuits or other legal, regulatory or other proceedings challenging or affecting this Agreement or the consummation of the transactions contemplated hereby;
 - (iii) use reasonable best efforts to have lifted or rescinded any injunction or restraining order or other order relating to it which may adversely affect the ability of the Parties to consummate the transactions contemplated hereby; and
- (c) use all reasonable best efforts to satisfy all conditions precedent set forth in Section 8.1 and Section 8.2 of this Agreement.

ARTICLE 8 - CONDITIONS

8.1 Mutual Conditions Precedent

The respective obligations of the Parties to complete the Transaction shall be subject to the satisfaction, on or before February 28, 2026, of the following conditions precedent, each of which may only be waived by the mutual consent of the Parties:

- (a) there shall not be in force any order or decree restraining or enjoining the consummation of the transactions contemplated by this Agreement and there shall be no proceeding , of a judicial or administrative nature or otherwise, in progress or threatened that relates to or results from the transactions contemplated by this Agreement that would, if successful, result in an order or ruling that would preclude completion of the transactions contemplated by this Agreement in accordance with the terms hereof or would otherwise be inconsistent with any required regulatory approvals which have been obtained;
- (b) this Agreement shall not have been terminated pursuant to Section 14.1;
- (c) the Vendor shall have received, if necessary, all required approvals of the TSX-V to the Transactions contemplated herein;
- (d) the Purchaser shall have received, if necessary, all required approvals of the TSX-V to the Transactions contemplated herein;

(e) the Closing Date Consideration Shares shall have been authorized for listing on the TSX-V, subject to official notice of issuance; and

(f) all other consents, waivers, permits, orders and approvals of any Governmental Authority, and the expiry of any waiting periods, in connection with, or required to permit the consummation of the Transaction herein shall have been obtained.

8.2 Purchaser's Conditions Precedent

The obligations of the Purchaser to complete the transactions contemplated by this Agreement shall also be subject to the satisfaction, on or before the Closing Date, of each of the following conditions precedent (each of which is for the exclusive benefit of the Purchaser and may be waived by the Purchaser):

(a) all covenants and agreements of the Vendor under this Agreement to be performed or observed on or before the Closing Date shall have been duly performed and observed by the Vendor in all material respects and the Purchaser shall have received a certificate of the Vendor addressed to the Purchaser and dated the Closing Date, signed on behalf of the Vendor by a director or senior executive officer of the Vendor, confirming the same as at the Closing Date;

(b) the representations and warranties of the Vendor set forth in this Agreement shall be true and correct in all material respects as of the date of this Agreement and as of the Closing Date as if made on and as of such date (except to the extent such representations and warranties speak as of a specified date which is earlier than the date of this Agreement, in which event such representations and warranties shall be true and correct in all respects as of such earlier specified date, or except as affected by transactions contemplated or permitted by this Agreement or otherwise consented to by the Purchaser) and the Purchaser shall have received a certificate of the Vendor addressed to the Purchaser and dated the Closing Date, signed on behalf of the Vendor by a director or senior executive officer of the Vendor, confirming the same as at the Closing Date;

(c) the board of directors of the Vendor shall have adopted all necessary resolutions, and all other necessary corporate action shall have been taken by the Vendor to permit the consummation of the Transaction;

(d) the Purchaser shall have received:

(i) the Title Documents duly executed by the Vendor, in form satisfactory to the Purchaser;

(ii) evidence satisfactory to the Purchaser that the Vendor is the registered owner of the Project on the register of real and immovable mining rights maintained by the MRNF in accordance with the *Mining Act* (Québec);

(iii) evidence satisfactory to the Purchaser that SOQUEM has waived its right of first refusal pursuant to the JV Agreement;

- (iv) all digital data relating to the Project in the control or possession of the Vendor; and
- (v) all such other documentation or evidence as is necessary to establish the consummation of the Transaction and the taking of all required corporate proceedings by the Vendor in connection with such Transaction;
- (e) the Purchaser and SOQUEM shall have entered into an amending agreement to the JV Agreement on terms satisfactory to the Purchaser;
- (f) There shall have been no Material Adverse Effect since the date of this Agreement; and
- (g) there shall not be pending or threatened any suit, action or proceeding by any Governmental Authority, in each case that has a reasonable likelihood of success:
 - (i) seeking to restrain or prohibit the consummation of the Transaction;
 - (ii) seeking to prohibit or materially limit the ownership or operation by the Purchaser of any material portion of the Project; or
 - (iii) seeking to impose limitations on the ability of the Purchaser to acquire or hold or exercise full rights of ownership of the Project.

The Purchaser may not rely on the failure to satisfy any of the above conditions precedent as a basis for non-compliance by it with its obligations under this Agreement if the condition precedent would have been satisfied but for a material default by the Purchaser in complying with its obligations hereunder.

8.3 Vendor's Conditions Precedent

The obligations of the Vendor to complete the transactions contemplated by this Agreement shall also be subject to the satisfaction, on or before the Closing Date, of each of the following conditions precedent (each of which is for the exclusive benefit of the Vendor and may be waived by the Vendor):

- (a) all covenants and agreements of the Purchaser under this Agreement to be performed or observed on or before the Closing Date shall have been duly performed by the Purchaser in all material respects and the Vendor shall have received a certificate of the Purchaser addressed to the Vendor and dated the Closing Date, signed on behalf of the Purchaser by a director or senior executive officer of the Purchaser confirming the same as at the Closing Date;
- (b) the representations and warranties of the Purchaser set forth in this Agreement shall be true and correct in all material respects as of the date of this Agreement and as of the Closing Date as if made on and as of such date (except to the extent such representations and warranties speak as of a specified date which is earlier than the date of this Agreement, in which event such representations and warranties shall be true and

correct in all material respects as of such earlier specified date, or except as affected by transactions contemplated or permitted by this Agreement or otherwise consented to by the Vendor) and the Vendor shall have received a certificate of the Purchaser addressed to the Vendor and dated the Closing Date, signed on behalf of the Purchaser by a director or senior executive officer of the Purchaser confirming the same as at the Closing Date; and

(c) the Vendor shall have received a certificate representing the Closing Date Consideration Shares;

(d) the board of directors of the Purchaser shall have adopted all necessary resolutions, and all other necessary corporate action shall have been taken by the Purchaser to permit the consummation of the Transaction and the issue of the Closing Date Consideration Shares; and

(e) there shall not be pending or threatened any suit, action or proceeding by any Governmental Authority, in each case that has a reasonable likelihood of success seeking to restrain or prohibit the consummation of the Transaction.

The Vendor may not rely on the failure to satisfy any of the above conditions precedent as a basis for non-compliance by the Vendor with its obligations under this Agreement if the condition precedent would have been satisfied but for a material default by the Vendor in complying with its obligations hereunder.

8.4 Notice and Cure Provisions

Each Party will give prompt notice to the other of the occurrence, or failure to occur, at any time from the date hereof until the Closing Date, of any event or state of facts which occurrence or failure would, or would be reasonably likely to:

(a) cause any of the representations or warranties of such Party contained herein to be untrue or inaccurate in any material respect between the date hereof and the Closing Date;

(b) result in the failure to comply with or satisfy any covenant or agreement to be complied with or satisfied by such Party hereunder prior to the Closing Date; or

(c) result in the failure to satisfy any of the conditions precedent in favour of the other Party hereto contained in Sections 8.1, 8.2 or 8.3 as the case may be.

Subject as herein provided, a Party may elect not to complete the transactions contemplated hereby pursuant to the conditions precedent contained in Sections 8.1, 8.2 or 8.3 in favour of such Party, or exercise any termination right arising therefrom, if forthwith, and in any event prior to the Closing Date, such Party has delivered a written notice to the other specifying in reasonable detail all breaches of covenants, representations and warranties or other matters which the Party delivering such notice is asserting as the basis for the non-fulfillment of the applicable condition precedent or the exercise of the termination right, as the case may be. If any such notice is delivered and the Party receiving such notice is proceeding diligently to cure such matter, if such matter is susceptible to being cured, the Party delivering such notice may not terminate this Agreement until the expiration of a period of ten (10) Business Days from such notice.

ARTICLE 9 INDEMNIFICATION

9.1 Indemnification

(a) The representations, warranties and covenants given in Section 2.4, Article 5, Article 6 and Article 7 constitute conditions on which the Parties have relied in entering into this Agreement, and shall survive the closing of the Transaction.

(b) Each Party shall indemnify and save harmless the other Party from any loss, damage or cost (including without limitation reasonable legal fees and disbursements) that arises as a result of or in connection with any claim whatsoever including any demand, action, motion, application, cause of action, dispute, trial, suit, administrative proceeding, quotation or re-quotation, order, judgement, decree or arbitral award, resulting from: (i) any non-fulfilment or breach of any covenant or agreement on the part of the Party contained in this Agreement or in any certificate or other document furnished by or on behalf of the Party pursuant to this Agreement; and (ii) any misrepresentation or any incorrectness in or breach of any representation or warranty of the Party in this Agreement or in any certificate or other document furnished by or on behalf of the Party pursuant to this Agreement.

(c) The obligation of a Party to defend the other Party pursuant to Section 9.1(b) is conditional upon the following:

(i) the Party that is subject to a third-party claim (the “**Indemnified Party**”) must promptly give notice thereof to the Party having the obligation to indemnify the Indemnified Party (the “**Indemnifying Party**”) and must thereafter cooperate fully in the defence of the claim; and

(ii) except if the Indemnifying Party does not timely initiate the defence of the third-party claim after receiving notice of the Indemnified Party, the Indemnifying Party shall have exclusive control of the defence and of any negotiation leading to the settlement of the third-party claim, provided that (1) the written consent of the Indemnified Party shall be obtained before any settlement is made final and conclusive, (2) the Indemnifying Party shall only have the right to control the defence and any negotiation leading to the settlement of the third-party claim to the extent it has confirmed in writing to the Indemnified Party its obligation to indemnify the Indemnified Party in respect of the third-party claim in accordance with this Article 9, and (3) the Indemnified Party shall also have the right to participate in the negotiation, settlement or defence of any third-party claim at its own expense.

ARTICLE 10 - CONFIDENTIALITY

10.1 Confidentiality

(a) The Parties and their respective Affiliates shall not issue or make any reports, statements or releases to the public with respect to this Agreement or the transactions contemplated herein without the written consent of Purchaser and Vendor. The Parties and their respective Affiliates shall not issue or make any reports, statements or releases

to the public with respect to the commercial terms of (i) this Agreement or the (ii) transactions contemplated herein, without the written consent of Purchaser and Vendor. However, the Parties and their respective Affiliates shall not be prohibited from issuing or making any reports, statements or releases to the public in order to comply with is required to disclose pursuant to applicable law or stock exchange rules.

(b) From and after the date of this Agreement, the Vendor shall, and shall cause each of its Affiliates and each of its and their respective Representatives to, keep confidential all information relating to the Project, other than information that:

- (i) is part of the public domain as of the date of this Agreement;
- (ii) becomes part of the public domain on or after the date of this Agreement other than as a result of a breach of these provisions by the Vendor;
- (iii) was received in good faith after date of this Agreement from an Independent Person who was lawfully in possession of such information free of any obligation of confidentiality; or
- (iv) the Vendor or any of its Affiliates is required to disclose pursuant to applicable law or stock exchange rules.

(c) From and after the date of this Agreement, each of the Vendor and the Purchaser shall, and shall cause each of their Affiliates and each of its and their Affiliates' Representatives to, keep confidential this Agreement and all information disclosed to it in connection with the Transactions by or on behalf of the other Party and relating to the other Party, except information that:

- (i) is part of the public domain as of the date of this Agreement;
- (ii) becomes part of the public domain on or after the date of this Agreement other than as a result of breach of these provisions;
- (iii) can be demonstrated to have been known or available to such Person before receipt of such information from the other Party or independently developed by such Person;
- (iv) was received in good faith from an Independent Person, who was lawfully in possession of such information free of any obligation of confidentiality; or
- (v) such Person or any of its Affiliates is required to disclose pursuant to applicable law or stock exchange rules.

10.2 Press Release

The Parties will consult with each other prior to issuing any press release or other public statement regarding this Agreement. In addition, each Party will, to the extent practicable, obtain prior

consent from the other Party before issuing any press release or public statement, except if such disclosure is required by law or by the rules and regulations of any regulatory authority or stock exchange having jurisdiction (a “**Regulatory News Release**”) and the other Party unreasonably withholds consent to such press release or other public statement or does not provide such consent in a timely manner. Notwithstanding the above, when practicable, where a Party requests consent from the other Party of any press release or public statement and the other Party has not responded to such request within forty eight (48) hours, then the Party proposing the press release or public statement will be entitled to proceed with its disclosure as if it had received consent from the other Party, which forty eight (48) hours period shall be reduced to twelve (12) hours in the case of a Regulatory News Release.

ARTICLE 11 - TRANSFERS

11.1 Transfers by the Purchaser

The Purchaser shall have the unrestricted right to transfer all or any of its rights, interests, and obligations under this Agreement, effective upon written notice thereof to the Vendor.

11.2 Transfers by the Vendor

Neither this Agreement nor any right, interest or obligation hereunder may be transferred or assigned by the Vendor by merger, amalgamation, operation of law or otherwise without the prior written consent of the Purchaser.

However, for greater certainty, and effective upon the Closing Time, the Vendor will be able to assign, transfer, pledge, hypothecate or otherwise convey all or any of its rights in the NSR pursuant to, and in accordance with, the terms thereof, without the prior written consent of the Purchaser, provided that it shall be a condition of such sale, assignment, transfer, pledge, hypothecation or other conveyance that the transferee or other counterparty to such transaction first execute and deliver to the Vendor and the Purchaser an instrument in writing pursuant to which such transferee or other counterparty agrees to be bound by the terms of the NSR and by all of the liabilities and obligations of the transferor thereunder in the same manner and to the same extent as though the transferee was an original party thereto in the first instance.

ARTICLE 12 - TAXES

12.1 The Parties hereby declare that they are duly registered under Part XI of the *Excise Tax Act* (Canada) (“**ETA**”) and Vendor hereby declares that it is duly registered under *An Act respecting the Québec Sales Tax* (Québec) (“**QSTA**”), that their registration has not been cancelled, and that their respective registration number(s) are as follows:

- (a) Vendor: QST: [REDACTED]
GST: [REDACTED]

- (b) Purchaser: GST: [REDACTED]

12.2 The Parties agree and acknowledge that the sale of the Project is not a “supply” for the purposes of the ETA pursuant to section 162 thereof, or of the QSTA pursuant to section 40

thereof, such that no Goods and Services Tax (GST) or Quebec Sales Tax (QST) shall be payable with respect thereto.

ARTICLE 13 - TRANSFER DUTIES

13.1 The Purchaser shall be responsible to pay exigible transfer duties, if any, pursuant to the *Act respecting duties on transfers of immovables* (Québec) (the "Act"), including any special duties imposed under Part III.7.0.1 of the *Taxation Act* (Québec), if applicable; in connection with the transfer of the Project on the Closing Date;

13.2 The Vendor and the Purchaser acknowledge and agree that the Project to be transferred on the Closing Date consists of immovable referred to in Section 8 of the *Mining Act* (Québec), and as such, that the transfer of the Project is exempted from transfer duties pursuant to Section 17(e) of the Act; and

13.3 The Vendor and the Purchaser shall complete and sign, on the Closing Date, one or more notices of disclosure required pursuant to Section 6 of the Act in respect of the transfer of the Project, in reliance upon the said exemption, and the Purchaser shall cause the said notices of disclosure to be filed with the municipality(ies) wherein the Project is located within ninety (90) days following the Closing Date.

ARTICLE 14 – TERMINATION

14.1 Termination

This Agreement may be terminated:

- (a) by mutual agreement of the Parties;
- (b) by either the Purchaser or the Vendor if:
 - (i) subject to Section 8.4, the other Party is in default of a covenant or obligation hereunder such that the conditions contained in Section 8.2(a) or 8.3(a) as applicable, would be incapable of satisfaction, provided the Party seeking to terminate this Agreement is not then in breach of this Agreement so as to cause any condition in favour of all Parties or in favour of the other Party not to be satisfied; or
 - (ii) subject to Section 8.4, any material representation or warranty of the other Party under this Agreement is untrue or incorrect and shall have become untrue or incorrect such that the condition contained in Section 8.2(b) or 8.3(b) as applicable, would be incapable of satisfaction, provided that the Party seeking to terminate this Agreement is not then in breach of this Agreement so as to cause any condition in favour of both Parties or in favour of the other Party not to be satisfied.
- (c) If this Agreement is terminated in accordance with the foregoing provisions of this Section 14.1, no Party shall have any further liability to perform its obligations hereunder, provided that nothing contained in this Section 14.1 shall relieve any Party from any liability

for any breach by it of this Agreement, including from any inaccuracy in its representations and warranties and any non-performance by it of its covenants made herein.

ARTICLE 15 – GENERAL

15.1 Notices

Any notice or other writing required or permitted to be given under this Agreement or for the purposes of this Agreement (in this Section referred to as a “**Notice**”) shall be in writing and shall be sufficiently given if delivered, or if sent by prepaid registered mail or if transmitted by electronic mail or other form of recorded communication tested prior to transmission to such Party:

- (a) in the case of a Notice to the Vendor at:

AZIMUT EXPLORATION INC.

110 De La Barre Street
Suite 224
Longueuil, QC
J4K 1A3

Attention: Jean-Marc Lulin, President and Chief Executive Officer
Email: [REDACTED]

- (b) in the case of a Notice to the Purchaser at:

Li-FT Power Ltd.

1030 West Georgia Street
Suite 1218
Vancouver, BC
V6E 2Y3

Attention: Francis MacDonald, President and Chief Executive Officer
Email: [REDACTED]

With a copy to:

OSLER, HOSKIN & HARCOURT LLP

1055 Dunsmuir Street
Suite 3000
Vancouver, BC
V7X 1K8

Attention: Alan Hutchison
Email: [REDACTED]

or at such other address as the Party to whom such Notice is to be given shall have last notified the Party giving the same in the manner provided in this Section 15.1. Any Notice delivered to the Party to whom it is addressed as provided above shall be deemed to have been given and received on the day it is so delivered at such address, provided that if such day is not a Business Day then the Notice shall be deemed to have been given and received on the next Business Day. Any Notice sent by prepaid registered mail shall be deemed to have been given and received on

the fifth Business Day following the date of its mailing. Any Notice transmitted by electronic mail or other form of recorded communication shall be deemed given and received on the first Business Day after its transmission.

15.2 Further Assurances

The Parties shall with reasonable diligence, do all such things and provide all such reasonable assurances as may be required to consummate the Transaction contemplated by this Agreement, and each Party shall provide such further deeds, documents or instruments (notarial, by private writing or otherwise) required by the other Party as may be reasonably necessary or desirable to effect the purpose of this Agreement and carry out its provisions.

12.3 Expenses

Each of the Parties shall be responsible for their own expenses in connection with the Transaction.

12.4 Amendment

This Agreement may not be amended or modified except by a written document executed by each of the Parties.

12.5 Binding Effect

This Agreement shall enure to the benefit of and be binding upon the Parties and their respective successors and permitted assigns.

12.6 Language

The Parties have agreed that this Agreement and all contracts, documents and notices relating to this Agreement be drawn up in the English language; *les parties aux présentes ont convenu que le présent contrat et tous les autres contrats, documents ou avis afférents aux présentes soient rédigés en langue anglaise.*

[Signature Page Follows]

IN WITNESS OF WHICH the Parties have duly executed this Agreement as of the date first written above.

AZIMUT EXPLORATION INC.

LI-FT POWER LTD.

Per: (s) *Jean-Marc Lulin*
Jean-Marc Lulin
President and Chief Executive Officer

Per: (s) *Francis MacDonald*
Francis MacDonald
President and Chief Executive Officer

ANNEXE A
DESCRIPTION DE LA PROPRIÉTÉ

| PROJECT | NTS | Row | Column | Surface (Ha) | Title | Title # | Status | Staking Date | Inscription Date | Expiry Date | 2025 Expenditures | Excess Expenditures | Required Expenditures | Renewal Cost | Renewal being processed |
|---------|-------|-----|--------|--------------|-------|---------|--------|--------------|------------------|-------------|-------------------|---------------------|-----------------------|--------------|-------------------------|
| Galinée | 33H01 | 29 | 12 | 51.6 | CDC | 2495711 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 29 | 11 | 51.6 | CDC | 2495710 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 29 | 10 | 51.6 | CDC | 2495709 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 29 | 19 | 51.6 | CDC | 2495718 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 16 | 51.59 | CDC | 2495287 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 24 | 38 | 51.64 | CDC | 2495555 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 21 | 51.59 | CDC | 2495723 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 20 | 51.59 | CDC | 2495291 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 19 | 51.59 | CDC | 2495290 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 1 | 51.59 | CDC | 2495279 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 17 | 51.59 | CDC | 2495288 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 2 | 51.59 | CDC | 2495280 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 15 | 51.59 | CDC | 2495286 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 14 | 51.59 | CDC | 2495285 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 13 | 51.59 | CDC | 2495284 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 12 | 51.59 | CDC | 2495283 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 11 | 51.59 | CDC | 2495282 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 10 | 51.59 | CDC | 2495722 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 9 | 51.59 | CDC | 2495721 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 30 | 18 | 51.59 | CDC | 2495289 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 9 | 51.58 | CDC | 2495469 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 13 | 51.57 | CDC | 2495493 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 17 | 51.58 | CDC | 2495477 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 16 | 51.58 | CDC | 2495476 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 15 | 51.58 | CDC | 2495475 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 14 | 51.58 | CDC | 2495474 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 13 | 51.58 | CDC | 2495473 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 12 | 51.58 | CDC | 2495472 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 19 | 51.58 | CDC | 2495479 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 10 | 51.58 | CDC | 2495470 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 20 | 51.58 | CDC | 2495480 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 8 | 51.58 | CDC | 2495468 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 7 | 51.58 | CDC | 2495467 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 6 | 51.58 | CDC | 2495466 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 5 | 51.58 | CDC | 2495465 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 4 | 51.58 | CDC | 2495464 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 3 | 51.58 | CDC | 2495463 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 2 | 51.58 | CDC | 2495462 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 1 | 51.58 | CDC | 2495461 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 11 | 51.58 | CDC | 2495471 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 3 | 51.57 | CDC | 2495483 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 24 | 36 | 51.64 | CDC | 2495553 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 11 | 51.57 | CDC | 2495491 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 10 | 51.57 | CDC | 2495490 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 9 | 51.57 | CDC | 2495489 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 8 | 51.57 | CDC | 2495488 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 7 | 51.57 | CDC | 2495487 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 6 | 51.57 | CDC | 2495486 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 1 | 18 | 51.58 | CDC | 2495478 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 4 | 51.57 | CDC | 2495484 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 3 | 58 | 51.56 | CDC | 2495458 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 2 | 51.57 | CDC | 2495482 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 1 | 51.57 | CDC | 2495481 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 5 | 51.57 | CDC | 2495485 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 60 | 51.59 | CDC | 2495442 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 3 | 60 | 51.56 | CDC | 2495460 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 1 | 55 | 51.57 | CDC | 2495444 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 59 | 51.59 | CDC | 2495441 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 58 | 51.59 | CDC | 2495440 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 57 | 51.59 | CDC | 2495439 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 56 | 51.58 | CDC | 2495438 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 55 | 51.58 | CDC | 2495437 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 54 | 51.58 | CDC | 2495436 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 53 | 51.58 | CDC | 2495435 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 52 | 51.58 | CDC | 2495434 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H08 | 2 | 14 | 51.57 | CDC | 2495494 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 3 | 57 | 51.56 | CDC | 2495457 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 2 | 60 | 51.57 | CDC | 2495456 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 2 | 59 | 51.57 | CDC | 2495455 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 2 | 58 | 51.57 | CDC | 2495454 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 2 | 57 | 51.57 | CDC | 2495453 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 2 | 56 | 51.57 | CDC | 2495452 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 2 | 55 | 51.56 | CDC | 2495451 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 1 | 54 | 51.57 | CDC | 2495443 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 1 | 60 | 51.58 | CDC | 2495449 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 1 | 59 | 51.58 | CDC | 2495448 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 1 | 58 | 51.58 | CDC | 2495447 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H07 | 1 | 57 | 51.58 | CDC | 2495446 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |

ANNEXE A
DESCRIPTION DE LA PROPRIÉTÉ

| PROJECT | NTS | Row | Column | Surface (Ha) | Title | Title # | Status | Staking Date | Inscription Date | Expiry Date | 2025 Expenditures | Excess Expenditures | Required Expenditures | Renewal Cost | Renewal being processed |
|---------|-------|-----|--------|--------------|-------|---------|--------|--------------|------------------|-------------|-------------------|---------------------|-----------------------|--------------|-------------------------|
| Galinée | 33H02 | 24 | 40 | 51.64 | CDC | 2495313 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 24 | 39 | 51.64 | CDC | 2495312 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 24 | 48 | 51.64 | CDC | 2495321 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 37 | 51.63 | CDC | 2495563 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 46 | 51.63 | CDC | 2495336 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 45 | 51.63 | CDC | 2495335 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 44 | 51.63 | CDC | 2495334 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 43 | 51.63 | CDC | 2495333 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 42 | 51.63 | CDC | 2495332 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 41 | 51.63 | CDC | 2495331 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 40 | 51.63 | CDC | 2495330 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 38 | 51.63 | CDC | 2495564 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 36 | 51.63 | CDC | 2495562 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 35 | 51.63 | CDC | 2495561 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 34 | 51.63 | CDC | 2495560 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 33 | 51.63 | CDC | 2495559 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 32 | 51.63 | CDC | 2495558 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 31 | 51.63 | CDC | 2495557 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 30 | 51.63 | CDC | 2495556 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 48 | 51.63 | CDC | 2495338 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 25 | 39 | 51.63 | CDC | 2495329 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 51 | 51.6 | CDC | 2495389 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 45 | 51.59 | CDC | 2495405 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 44 | 51.59 | CDC | 2495404 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 58 | 51.61 | CDC | 2495396 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 57 | 51.61 | CDC | 2495395 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 56 | 51.6 | CDC | 2495394 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 55 | 51.6 | CDC | 2495393 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 54 | 51.6 | CDC | 2495392 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 40 | 51.6 | CDC | 2495378 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 52 | 51.6 | CDC | 2495390 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 48 | 51.59 | CDC | 2495408 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 50 | 51.6 | CDC | 2495388 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 49 | 51.6 | CDC | 2495387 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 48 | 51.6 | CDC | 2495386 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 47 | 51.6 | CDC | 2495385 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 46 | 51.6 | CDC | 2495384 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 45 | 51.6 | CDC | 2495383 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 44 | 51.6 | CDC | 2495382 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 53 | 51.6 | CDC | 2495391 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 56 | 51.59 | CDC | 2495416 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 24 | 37 | 51.64 | CDC | 2495554 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 48 | 51.58 | CDC | 2495430 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 47 | 51.58 | CDC | 2495429 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 46 | 51.58 | CDC | 2495428 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 45 | 51.58 | CDC | 2495427 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 44 | 51.58 | CDC | 2495426 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 60 | 51.6 | CDC | 2495420 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 59 | 51.6 | CDC | 2495419 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 46 | 51.59 | CDC | 2495406 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 57 | 51.6 | CDC | 2495417 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 47 | 51.59 | CDC | 2495407 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 55 | 51.59 | CDC | 2495415 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 54 | 51.59 | CDC | 2495414 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 53 | 51.59 | CDC | 2495413 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 52 | 51.59 | CDC | 2495412 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 51 | 51.59 | CDC | 2495411 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 50 | 51.59 | CDC | 2495410 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 49 | 51.59 | CDC | 2495409 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 39 | 51.6 | CDC | 2495377 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 29 | 58 | 51.6 | CDC | 2495418 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 34 | 51.61 | CDC | 2495578 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 43 | 51.61 | CDC | 2495365 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 42 | 51.61 | CDC | 2495364 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 41 | 51.61 | CDC | 2495363 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 40 | 51.61 | CDC | 2495362 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 39 | 51.61 | CDC | 2495361 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 38 | 51.61 | CDC | 2495582 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 37 | 51.61 | CDC | 2495581 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 43 | 51.6 | CDC | 2495381 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 35 | 51.61 | CDC | 2495579 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 46 | 51.61 | CDC | 2495368 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 33 | 51.61 | CDC | 2495577 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 32 | 51.61 | CDC | 2495576 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 31 | 51.61 | CDC | 2495575 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 30 | 51.61 | CDC | 2495574 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 30 | 50 | 51.58 | CDC | 2495432 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 36 | 51.61 | CDC | 2495580 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |

ANNEXE A
DESCRIPTION DE LA PROPRIÉTÉ

| PROJECT | NTS | Row | Column | Surface (Ha) | Title | Title # | Status | Staking Date | Inscription Date | Expiry Date | 2025 Expenditures | Excess Expenditures | Required Expenditures | Renewal Cost | Renewal being processed |
|---------|-------|-----|--------|--------------|-------|---------|--------|--------------|------------------|-------------|-------------------|---------------------|-----------------------|--------------|-------------------------|
| Galinée | 33H02 | 27 | 54 | 51.61 | CDC | 2495376 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 28 | 38 | 51.6 | CDC | 2495585 | Active | 2017-05-20 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 44 | 51.61 | CDC | 2495366 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 45 | 51.61 | CDC | 2495367 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 53 | 51.61 | CDC | 2495375 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 52 | 51.61 | CDC | 2495374 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 51 | 51.61 | CDC | 2495373 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 50 | 51.61 | CDC | 2495372 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 49 | 51.61 | CDC | 2495371 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 48 | 51.61 | CDC | 2495370 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H02 | 27 | 47 | 51.61 | CDC | 2495369 | Active | 2017-05-19 | 2017-06-12 | 2027-06-11 | | | | | |
| Galinée | 33H01 | 27 | 26 | 51.62 | CDC | 2522766 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H01 | 28 | 26 | 51.61 | CDC | 2522768 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H01 | 30 | 26 | 51.59 | CDC | 2522776 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H01 | 29 | 26 | 51.6 | CDC | 2522770 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H01 | 30 | 25 | 51.59 | CDC | 2522775 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H01 | 30 | 24 | 51.59 | CDC | 2522774 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H01 | 30 | 23 | 51.59 | CDC | 2522773 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H01 | 30 | 22 | 51.59 | CDC | 2522772 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 1 | 26 | 51.58 | CDC | 2522783 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 1 | 25 | 51.58 | CDC | 2522782 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 1 | 24 | 51.58 | CDC | 2522781 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 1 | 23 | 51.58 | CDC | 2522780 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 1 | 22 | 51.58 | CDC | 2522779 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 1 | 21 | 51.58 | CDC | 2522778 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 14 | 51.55 | CDC | 2522806 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 22 | 51.55 | CDC | 2522812 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 21 | 51.55 | CDC | 2522811 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 20 | 51.55 | CDC | 2522810 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 17 | 51.55 | CDC | 2522809 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 24 | 51.55 | CDC | 2522814 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 15 | 51.55 | CDC | 2522807 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 25 | 51.55 | CDC | 2522815 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 13 | 51.55 | CDC | 2522805 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 12 | 51.55 | CDC | 2522804 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 11 | 51.55 | CDC | 2522803 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 10 | 51.55 | CDC | 2522802 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 9 | 51.55 | CDC | 2522801 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 16 | 51.55 | CDC | 2522808 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 5 | 11 | 51.54 | CDC | 2522822 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 5 | 16 | 51.54 | CDC | 2522827 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 5 | 15 | 51.54 | CDC | 2522826 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 5 | 14 | 51.54 | CDC | 2522825 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 23 | 51.55 | CDC | 2522813 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 5 | 12 | 51.54 | CDC | 2522823 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 5 | 10 | 51.54 | CDC | 2522821 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 5 | 9 | 51.54 | CDC | 2522820 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 4 | 26 | 51.55 | CDC | 2522816 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 5 | 13 | 51.54 | CDC | 2522824 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 2 | 23 | 51.57 | CDC | 2522788 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 2 | 26 | 51.57 | CDC | 2522791 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 2 | 24 | 51.57 | CDC | 2522789 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 2 | 22 | 51.57 | CDC | 2522787 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 2 | 21 | 51.57 | CDC | 2522786 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 2 | 20 | 51.57 | CDC | 2522785 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 2 | 25 | 51.57 | CDC | 2522790 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 3 | 26 | 51.56 | CDC | 2522799 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 3 | 25 | 51.56 | CDC | 2522798 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 3 | 24 | 51.56 | CDC | 2522797 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 3 | 23 | 51.56 | CDC | 2522796 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 3 | 22 | 51.56 | CDC | 2522795 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 3 | 21 | 51.56 | CDC | 2522794 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 3 | 20 | 51.56 | CDC | 2522793 | Active | 2018-08-31 | 2018-09-10 | 2026-09-09 | | | | | |
| Galinée | 33H08 | 6 | 5 | 51.53 | CDC | 2543175 | Active | 2019-08-14 | 2019-09-06 | 2026-09-05 | | | | | |
| Galinée | 33H08 | 6 | 4 | 51.53 | CDC | 2543174 | Active | 2019-08-14 | 2019-09-06 | 2026-09-05 | | | | | |
| Galinée | 33H08 | 5 | 5 | 51.54 | CDC | 2543173 | Active | 2019-08-14 | 2019-09-06 | 2026-09-05 | | | | | |
| Galinée | 33H08 | 5 | 4 | 51.54 | CDC | 2543172 | Active | 2019-08-14 | 2019-09-06 | 2026-09-05 | | | | | |
| Galinée | 33H02 | 19 | 52 | 51.69 | CDC | 2541921 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |
| Galinée | 33H02 | 20 | 57 | 51.68 | CDC | 2541942 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |
| Galinée | 33H02 | 19 | 58 | 51.69 | CDC | 2541927 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |
| Galinée | 33H02 | 19 | 57 | 51.69 | CDC | 2541926 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |
| Galinée | 33H02 | 19 | 56 | 51.69 | CDC | 2541925 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |
| Galinée | 33H02 | 19 | 55 | 51.69 | CDC | 2541924 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |
| Galinée | 33H02 | 19 | 53 | 51.69 | CDC | 2541922 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |
| Galinée | 33H02 | 19 | 51 | 51.69 | CDC | 2541920 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |
| Galinée | 33H02 | 19 | 50 | 51.69 | CDC | 2541919 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |
| Galinée | 33H02 | 19 | 49 | 51.69 | CDC | 2541918 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |
| Galinée | 33H02 | 19 | 48 | 51.69 | CDC | 2541917 | Active | 2019-06-25 | 2019-07-26 | 2026-07-25 | | | | | |

ANNEXE A
DESCRIPTION DE LA PROPRIÉTÉ


| PROJECT | NTS | Row | Column | Surface (Ha) | Title | Title # | Status | Staking Date | Inscription Date | Expiry Date | 2025 Expenditures | Excess Expenditures | Required Expenditures | Renewal Cost | Renewal being processed |
|---------|-------|-----|--------|--------------|-------|---------|--------|--------------|------------------|-------------|-------------------|---------------------|-----------------------|--------------|-------------------------|
| Galinée | 33H01 | 25 | 10 | 51.64 | CDC | 2518571 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 26 | 7 | 51.63 | CDC | 2518579 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 26 | 6 | 51.63 | CDC | 2518578 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 26 | 5 | 51.63 | CDC | 2518577 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 25 | 15 | 51.64 | CDC | 2518576 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 25 | 14 | 51.64 | CDC | 2518575 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 25 | 13 | 51.64 | CDC | 2518574 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 25 | 11 | 51.64 | CDC | 2518572 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 25 | 9 | 51.64 | CDC | 2518570 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 25 | 8 | 51.64 | CDC | 2518569 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 25 | 7 | 51.64 | CDC | 2518568 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 25 | 6 | 51.64 | CDC | 2518567 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 25 | 5 | 51.64 | CDC | 2518566 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 25 | 12 | 51.64 | CDC | 2518573 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 27 | 7 | 51.62 | CDC | 2518582 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 27 | 6 | 51.62 | CDC | 2518581 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H01 | 27 | 5 | 51.62 | CDC | 2518580 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H07 | 1 | 49 | 51.57 | CDC | 2518846 | Active | 2018-05-17 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H07 | 1 | 48 | 51.57 | CDC | 2518845 | Active | 2018-05-17 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H07 | 1 | 47 | 51.57 | CDC | 2518844 | Active | 2018-05-17 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H07 | 1 | 46 | 51.57 | CDC | 2518843 | Active | 2018-05-17 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H07 | 1 | 44 | 51.57 | CDC | 2518841 | Active | 2018-05-17 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H07 | 1 | 45 | 51.57 | CDC | 2518842 | Active | 2018-05-17 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H02 | 25 | 58 | 51.64 | CDC | 2518642 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H02 | 26 | 27 | 51.62 | CDC | 2518647 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H02 | 24 | 58 | 51.65 | CDC | 2518640 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H02 | 26 | 58 | 51.63 | CDC | 2518648 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H02 | 27 | 27 | 51.61 | CDC | 2518653 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H02 | 28 | 27 | 51.6 | CDC | 2518659 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H02 | 27 | 58 | 51.62 | CDC | 2518654 | Active | 2018-05-13 | 2018-05-28 | 2026-05-27 | | | | | |
| Galinée | 33H02 | 19 | 60 | 51.7 | CDC | 2707640 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 59 | 51.7 | CDC | 2707639 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 36 | 51.7 | CDC | 2707599 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 41 | 51.69 | CDC | 2707638 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 45 | 51.7 | CDC | 2707608 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 54 | 51.7 | CDC | 2707617 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 53 | 51.7 | CDC | 2707616 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 52 | 51.7 | CDC | 2707615 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 51 | 51.7 | CDC | 2707614 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 50 | 51.7 | CDC | 2707613 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 49 | 51.7 | CDC | 2707612 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 48 | 51.7 | CDC | 2707611 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 46 | 51.7 | CDC | 2707609 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 57 | 51.7 | CDC | 2707620 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 44 | 51.7 | CDC | 2707607 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 43 | 51.7 | CDC | 2707606 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 42 | 51.7 | CDC | 2707605 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 41 | 51.7 | CDC | 2707604 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 40 | 51.7 | CDC | 2707603 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 39 | 51.7 | CDC | 2707602 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 38 | 51.7 | CDC | 2707601 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H01 | 16 | 1 | 51.73 | CDC | 2707554 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 47 | 51.7 | CDC | 2707610 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 31 | 51.69 | CDC | 2707628 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 40 | 51.69 | CDC | 2707637 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 39 | 51.69 | CDC | 2707636 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 38 | 51.69 | CDC | 2707635 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 37 | 51.69 | CDC | 2707634 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 36 | 51.69 | CDC | 2707633 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 35 | 51.69 | CDC | 2707632 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 34 | 51.69 | CDC | 2707631 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 55 | 51.7 | CDC | 2707618 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 32 | 51.69 | CDC | 2707629 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 56 | 51.7 | CDC | 2707619 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 30 | 51.69 | CDC | 2707627 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 29 | 51.69 | CDC | 2707626 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 28 | 51.69 | CDC | 2707625 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 27 | 51.69 | CDC | 2707624 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 60 | 51.71 | CDC | 2707623 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 59 | 51.71 | CDC | 2707622 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 58 | 51.7 | CDC | 2707621 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 19 | 33 | 51.69 | CDC | 2707630 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 35 | 51.7 | CDC | 2707598 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 18 | 37 | 51.7 | CDC | 2707600 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H01 | 19 | 1 | 51.7 | CDC | 2707557 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H01 | 18 | 1 | 51.71 | CDC | 2707556 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H01 | 17 | 1 | 51.72 | CDC | 2707555 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |
| Galinée | 33H02 | 17 | 39 | 51.71 | CDC | 2707568 | Active | 2023-01-22 | 2023-01-22 | 2026-01-21 | | | | | |

ANNEXE A
DESCRIPTION DE LA PROPRIÉTÉ

| PROJECT | NTS | Row | Column | Surface (Ha) | Title | Title # | Status | Staking Date | Inscription Date | Expiry Date | 2025 Expenditures | Excess Expenditures | Required Expenditures | Renewal Cost | Renewal being processed |
|---------|-------|-----|--------|--------------|-------|---------|--------|--------------|------------------|-------------|-------------------|---------------------|-----------------------|--------------|-------------------------|
| Galinée | 33H07 | 1 | 50 | 51.57 | CDC | 2507852 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H07 | 2 | 52 | 51.56 | CDC | 2507858 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H07 | 1 | 53 | 51.57 | CDC | 2507855 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H07 | 2 | 53 | 51.56 | CDC | 2507859 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H07 | 2 | 51 | 51.56 | CDC | 2507857 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H07 | 2 | 50 | 51.56 | CDC | 2507856 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 26 | 29 | 51.62 | CDC | 2507839 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 25 | 57 | 51.63 | CDC | 2507837 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 25 | 56 | 51.63 | CDC | 2507836 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 25 | 55 | 51.63 | CDC | 2507835 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 26 | 28 | 51.62 | CDC | 2507838 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 26 | 55 | 51.62 | CDC | 2507840 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 24 | 56 | 51.64 | CDC | 2507833 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 24 | 57 | 51.64 | CDC | 2507834 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 26 | 56 | 51.62 | CDC | 2507841 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 27 | 29 | 51.61 | CDC | 2507844 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 27 | 28 | 51.61 | CDC | 2507843 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 28 | 31 | 51.6 | CDC | 2507851 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 28 | 30 | 51.6 | CDC | 2507850 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 28 | 29 | 51.6 | CDC | 2507849 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 28 | 28 | 51.6 | CDC | 2507848 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 27 | 57 | 51.62 | CDC | 2507847 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 27 | 55 | 51.61 | CDC | 2507845 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 26 | 57 | 51.62 | CDC | 2507842 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |
| Galinée | 33H02 | 27 | 56 | 51.61 | CDC | 2507846 | Active | 2017-09-17 | 2017-12-14 | 2025-12-13 | | | | | |

SCHEDULE "A" (CONTINUED)

MAP OF PROJECT AND EXCLUSIVE EXPLORATION RIGHTS



**GALINÉE PROPERTY
Claim Map**

□ Active claim

1:250,000

0 2.5 5 7.5 10
km

UTM zone 18 Projection - NAD83

Date: 2025-12-08

SCHEDULE "B"

NET SMELTER RETURNS ROYALTY

[REDACTED]